Current Research Studies

SC-4020 VITAS: Atezolizumab in combination with chemotherapy for pediatric relapsed/refractory solid tumors: An open-label, phase I/II, single-arm, multi-center trial

SC-4020 VITAS

  • Condition(s): Soft Tissue
  • Phase: II
  • Clinicaltrials.gov ID: NCT04796012

What is the goal of the study?

Determine the feasibility of administering vincristine, irinotecan, temozolomide, and atezolizumab simultaneously in children with relapsed or refractory solid tumors. Determine the objective response rate (ORR) of children with PD L1(+) relapsed or refractory rhabdomyosarcoma treated with vincristine, irinotecan, temozolomide, and atezolizumab.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: